BG
ADAP

Bellevue Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Bellevue Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-131,135
Closed -$754K – 138
2018
Q4 		$754K Buy
131,135
+72,600
+124% +$536K 0.05% 125
2018
Q3 		$794K Sell
58,535
-1,400
-2% -$14.7K 0.05% 130
2018
Q2 		$711K Buy
+59,935
New +$747K 0.06% 128

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group's ADAP Position: Q1 2019 in Review

Bellevue Group sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 131,135 shares — an estimated $754K sold.

Bellevue Group first reported a position in ADAP in Q2 2018 and held it in 3 quarters. The position peaked at $794K in Q3 2018. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

  • Bellevue Group reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Bellevue Group sold 131,135 Adaptimmune Therapeutics shares in Q1 2019, an estimated $754K.
  • Bellevue Group first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 3 quarters.
  • Bellevue Group's Adaptimmune Therapeutics position peaked at $794K in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.